OTTAWA, ONTARIO, November 14, 2012 - Avivagen Inc. (TSXV:VIV), a wellness company, recently participated in a trade mission along with several other commercial bioscience organizations as part of the Atlantic Region's fall International BioPartnering Mission. Avivagen met with representatives from a number of international animal health companies and had discussions with the goal of entering into additional distribution and/or partnership agreements. Avivagen CEO David Hankinson said. "This was a great opportunity for us to meet face-to-face with experts and key commercial representatives from both Asia and Latin America. The mission was very productive in helping develop Avivagen's plans for introducing into the Asian and Latin American markets the Company's food animal and companion animal products that are based on our proprietary OxC-beta product platform."

The international BioPartnering initiative is organized by the Atlantic Canada BioIndustries Alliance and includes one-on-one business meetings between invited foreign guests and the host company, pitch presentations, information sessions and networking events. These missions are designed to showcase Canadian bioscience company capabilities and to help form partnerships leading to export sales, licensing agreements and Research and Development projects.

About OxC-beta

OxC-beta is Avivagen's proprietary, concentrated source of oxidized carotenoid, containing oxidation compounds that occur extensively in the plant world in minute amounts. Results of clinical trials in animals and in vitro studies indicate OxC-beta helps support immune function, which can result in general overall health improvement. Specific benefits include better growth, utilization of feed and decreased mortality in poultry and swine. It is currently available for dogs of all ages in the form of Oximunol(TM) Chewables, which work with a dog's immune system to optimize overall health and well-being.

About Avivagen

Avivagen, a wellness company, is developing and delivering products for animals and humans to assist in optimizing health and daily quality of life. Avivagen is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at www.avivagen.com.

Forward Looking Statements
This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Avivagen Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:

David Hankinson

CEO, Avivagen Inc.

Phone: 902-825-9270

d.hankinson@avivagen.com

Graham Burton, PhD

President and Co-Founder, Avivagen Inc.

Phone: 613-990-0969

g.burton@avivagen.com